首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   28篇
  免费   0篇
  国内免费   6篇
综合类   8篇
水产渔业   4篇
畜牧兽医   22篇
  2019年   3篇
  2018年   1篇
  2014年   3篇
  2012年   1篇
  2011年   1篇
  2010年   2篇
  2009年   1篇
  2008年   1篇
  2007年   3篇
  2006年   3篇
  2005年   1篇
  2004年   2篇
  2003年   4篇
  2002年   1篇
  2001年   5篇
  2000年   2篇
排序方式: 共有34条查询结果,搜索用时 15 毫秒
1.
The aim of this study was to determine the pharmacokinetics/pharmacodynamics of enrofloxacin (ENR) and danofloxacin (DNX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. The study was performed on twenty‐four calves that were determined to be premature by anamnesis and general clinical examination. Premature calves were randomly divided into four groups (six premature calves/group) according to a parallel pharmacokinetic (PK) design as follows: ENR‐IV (10 mg/kg, IV), ENR‐IM (10 mg/kg, IM), DNX‐IV (8 mg/kg, IV), and DNX‐IM (8 mg/kg, IM). Plasma samples were collected for the determination of tested drugs by high‐pressure liquid chromatography with UV detector and analyzed by noncompartmental methods. Mean PK parameters of ENR and DNX following IV administration were as follows: elimination half‐life (t1/2λz) 11.16 and 17.47 hr, area under the plasma concentration–time curve (AUC0‐48) 139.75 and 38.90 hr*µg/ml, and volume of distribution at steady‐state 1.06 and 4.45 L/kg, respectively. Total body clearance of ENR and DNX was 0.07 and 0.18 L hr?1 kg?1, respectively. The PK parameters of ENR and DNX following IM injection were t1/2λz 21.10 and 28.41 hr, AUC0‐48 164.34 and 48.32 hr*µg/ml, respectively. The bioavailability (F) of ENR and DNX was determined to be 118% and 124%, respectively. The mean AUC0‐48CPR/AUC0‐48ENR ratio was 0.20 and 0.16 after IV and IM administration, respectively, in premature calves. The results showed that ENR (10 mg/kg) and DNX (8 mg/kg) following IV and IM administration produced sufficient plasma concentration for AUC0‐24/minimum inhibitory concentration (MIC) and maximum concentration (Cmax)/MIC ratios for susceptible bacteria, with the MIC90 of 0.5 and 0.03 μg/ml, respectively. These findings may be helpful in planning the dosage regimen for ENR and DNX, but there is a need for further study in naturally infected premature calves.  相似文献   
2.
Colibacillosis is a systemic disease responsible for important economic losses in poultry breeding; fluoroquinolones, including danofloxacin, are used to treat diseased animals. The purpose of the present study was to estimate pharmacokinetic–pharmacodynamic (PK-PD) surrogates for bacteriostasis, bactericidal activity and bacterial elimination against Escherichia coli O78/K80, using a PK-PD approach, for danofloxacin in turkeys after oral administration. Eight healthy turkeys, breed BUT 9, were included in a two-way crossover study. The drug was administered intravenously (i.v.) and orally at a dose rate of 6 mg/kg bw. The values of the elimination half-life and the total body clearance after i.v. administration were 8.64 ± 2.35 h and 586.76 ± 136.67 ml kg-1h-1, respectively. After oral administration, the values of the absolute bioavailability and the elimination half-life were 78.37± 17.35% and 9.74± 2.93 h, respectively. The minimum inhibitory concentration against the investigated strain in turkey serum was 0.25 μg/ml, four times higher than in broth. The lowest effective ex vivo AUC24/MIC ratios required for bacteriostasis, bactericidal activity, and total killing of E. coliO78/K80 were 0.416 h, 1.9 h and 6.73 h, respectively. The oral dose of 6 mg/kg used in the present study could be interpreted as being sufficient to eliminate E. coli with an MIC 0.25 μ g/ml. However, considering the demand that antimicrobial resistance should be avoided by complete bacterial elimination, PK-PD considerations suggest that an even higher dose of 32 mg/kg per day or 0.7 mg/kcal per day should be evaluated in clinical trials.  相似文献   
3.
The aim of the present study was to determine the pharmacokinetics (PKs) and bioavailability of danofloxacin in chukar partridge (Alectoris chukar) following intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations at a dose of 10 mg/kg. A total of eight clinically healthy chukar partridges weighing 480 ± 45 g were used for the investigation. The study was performed in a crossover design (2 × 2 × 2 × 2) with a 15‐day washout period between two administrations in four periods. The plasma concentrations of danofloxacin were determined using reversed‐phase high‐performance liquid chromatography. Noncompartmental PK parameters were also estimated. No local or systemic adverse drug effects were observed in any of the chukar partridges. The mean elimination half‐life ranged between 8.18 and 12.08 hr and differed statistically among administration routes. The mean peak plasma concentrations of danofloxacin following IM, SC, and PO administrations were 8.05, 9.58, and 3.39 μg/ml at 0.5, 1, and 4 hr, respectively. Following IM, SC, and PO administrations, the mean bioavailability was 86.33%, 134.40%, and 47.62%, respectively. The mean total clearance and volume of distribution at steady‐state following IV administration were 0.13 L hr?1 kg?1 and 0.96 L/kg, respectively. These data, including favorable PKs and the absence of adverse drug effects, suggest that danofloxacin is a useful antibiotic in chukar partridges.  相似文献   
4.
为了解猪胸膜肺炎放线杆菌对达氟沙星的敏感性和达氟沙星的杀菌效果,收集和分离48株猪胸膜肺炎放线杆菌,采用微量肉汤稀释法和菌落计数法对体外药物敏感性试验和生长曲线、杀菌曲线进行了研究。猪胸膜肺炎放线杆菌对氨苄西林、磺胺异恶唑、头孢噻呋、大观霉素、黏菌素耐药率高,对阿莫西林/克拉维酸、复方新诺明、氟苯尼考、多西环素、庆大霉素、四环素、恩诺沙星、氧氟沙星、达氟沙星敏感。达氟沙星最小抑菌浓度(MIC)集中在0.0078μg/m L。达氟沙星浓度在MIC及以上时,随浓度升高,杀菌时间缩短,为典型的浓度依赖型抗生素。该试验结果可用于指导猪传染性胸膜肺炎的临床预防和治疗。  相似文献   
5.
将260只28日龄试验鸡(体质量215~230 g)随机分成5组:健康对照组20只,甲磺酸达氟沙星溶液静注给药组和内服给药组、甲磺酸达氟沙星脂质体静注给药组和内服给药组,每组60只。以5 mg/kg体质量剂量分别采用静脉注射和内服2种给药途径给予健康蛋雏鸡甲磺酸达氟沙星溶液和脂质体混悬液,于给药后0.167、0.333、0.5、0.75、1、1.5、2、4、6、9、12、24 h各剖杀5只鸡,取血液、肝脏、肾脏、肺脏和肌肉样品。采用反相HPLC色谱内标法测定各组织中达氟沙星浓度。应用MCPKP分析软件处理血浆药物浓度-时间数据,比较2种剂型的组织药动学参数。结果显示,与溶液组相比,甲磺酸达氟沙星脂质体组肝脏、肺脏中的药物分布明显提高,肾脏中的分布降低;通过相对摄取率、靶向效率和峰浓度比3个靶向指标的对比,脂质体组明显提高了肺部靶向性,且在肺部有一定的缓释作用。  相似文献   
6.
采用荧光分光光度法测定了甲磺酸达氟沙星粉的含量。激发和发射波长分别为350nm和448 nm,平均回收率为102.5%,RSD为1.1%。在0.01~5μg/mL范围内,其荧光强度与浓度线性关系良好。  相似文献   
7.
HPLC法测定鸡肉中达氟沙星残留量的测量不确定度评定   总被引:1,自引:0,他引:1  
建立了高效液相色谱法(HPLC)测定鸡肉中达氟沙星残留量的测量不确定度评定的数学模型,对测量过程中的不确定度来源进行逐项分析和合成,得出了高效液相色谱法测定鸡肉中达氟沙星残留量的不确定度结果。  相似文献   
8.
达氟沙星对施氏鲟非特异性免疫功能的影响   总被引:1,自引:0,他引:1  
采用经口灌服的方法,分别用20、50和100 mg.kg-1达氟沙星对施氏鲟连续给药20 d(每天1次),并于给药后第5、10、15和20天测定非特异性免疫指标.结果表明:达氟沙星对肝脏和血清溶菌酶含量有抑制作用;20和50 mg.kg-1组对血清中酚氧化酶活力先诱导后抑制,100 mg.kg-1组则始终表现抑制作用;该药使白细胞数量和细胞吞噬百分比降低,但对白细胞吞噬指数及肝脏和脾脏系数无显著影响(P>0.05).可见,达氟沙星使施氏鲟的非特异性免疫能力降低,但对免疫器官的生长指数没有明显的影响.  相似文献   
9.
达氟沙星对史氏鲟红细胞抗氧化功能及微核形成的影响   总被引:1,自引:0,他引:1  
卢彤岩 《水产学报》2006,30(5):591-596
2004年5月至7月间,用20 mg·kg-1、50 mg·kg-1和100 mg·kg-1剂量对史氏鲟经口灌服达氟沙星20 d,分别于第5、10、15 和20天定红细胞SOD、CAT、Na+、K+ATP酶、GST、GSHPX等抗氧化酶活性及丙二醛(MDA)含量,以评价达氟沙星对史氏鲟抗氧化防御功能的影响,同时进行红细胞微核率和总核异常率的测定。结果表明实验第5天各实验组红细胞SOD活性均显著高于对照组;各实验组红细胞中CAT的活性明显高于对照组;红细胞Na+、K+ATP酶活性没有明显的改变。实验第20天时100 mg·kg-1剂量组GSHPX活性明显高于对照组及其他剂量组(P<0.05);GST活性及MDA含量没有明显的影响。达氟沙星在实验剂量内对史氏鲟红细胞核微核率没有明显的影响,但核异常率呈明显升高。  相似文献   
10.
选用 4~ 5周龄健康蛋雏鸡 12 5只 ,按 5 mg/kg的剂量进行静脉注射和内服单诺沙星的药动学研究及生物利用研究。高效液相色谱内标法测定血浆中药物浓度 ,MCPKP药动学程序处理药时数据。静脉注射和内服给药后血药浓度—时间数据分别符合无吸收因素二室开放式模型和一级吸收一室开放式模型。静脉注射给药的主要药动学参数为 :t1 /2α=0 .3313h、t1 /2β= 5 .994 0 h、Vd=7.5 2 4 6 L/kg、AU C=5 .6 916 μg/m l· h、CLB=0 .8935 L/kg· h。内服给药后主要药动学参数为 :t1 /2 Ka=0 .30 2 9h、t1 /2 K=6 .5 12 8h、tmax=1.2 10 0 h、Cmax=0 .5 15 9μg/m l、AU C=5 .132 9μg/ml· h。生物利用度为 90 .18%。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号